Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple
Immunovant (IMVT) has been a swingy biotech name lately, with shares down over the past month but still up sharply over the past 3 months. This reflects shifting expectations around its autoimmune pipeline.
See our latest analysis for Immunovant.
Looking past the recent pullback, Immunovant’s roughly 36.6% 3 month share price return contrasts with a weaker year to date share price and a negative 1 year total shareholder return. This suggests momentum has recently rebuilt as investors reassess its autoimmune opportunity.
If Immunovant’s volatility has your attention, it could be a good moment to explore other innovative healthcare stocks that might complement or balance a biotech focused portfolio.
With shares still…
